Cytokine release syndrome, grade 5
ICD-10 D89.835 is a billable code used to indicate a diagnosis of cytokine release syndrome, grade 5.
Cytokine release syndrome (CRS) is a severe systemic inflammatory response that can occur following certain therapies, particularly immunotherapies such as CAR T-cell therapy and monoclonal antibodies. Grade 5 CRS is characterized by life-threatening complications, including multi-organ failure, severe hypotension, and respiratory distress. Clinically, patients may present with high fever, tachycardia, hypotension, and altered mental status. The pathophysiology involves the overproduction of cytokines, leading to a cascade of inflammatory responses that can overwhelm the body's regulatory mechanisms. Management of grade 5 CRS typically requires intensive care support, including vasopressors, oxygen therapy, and potentially the use of immunosuppressive agents such as tocilizumab. Accurate coding of this condition is crucial for appropriate reimbursement and tracking of treatment outcomes, as it reflects the severity of the patient's condition and the complexity of care required.
Detailed clinical notes on patient history, treatment regimen, and response to therapy.
Patients receiving CAR T-cell therapy who develop severe CRS.
Ensure documentation reflects the severity of CRS and any multi-organ involvement.
Comprehensive records of vital signs, interventions, and response to treatment.
Management of patients in the ICU with grade 5 CRS requiring intensive monitoring.
Document all supportive measures and their effectiveness in managing CRS.
Used when administering chemotherapy that may lead to CRS.
Document the drug administered, dosage, and patient response.
Oncology specialists should ensure accurate coding of the chemotherapy regimen.
Key symptoms include high fever, severe hypotension, respiratory distress, altered mental status, and multi-organ failure.
Management typically involves intensive care support, including vasopressors, oxygen therapy, and immunosuppressive agents like tocilizumab.
